Double blind, multinational, multicentre, parallel-group design clinical trial of the efficacy and tolerability of CHF 1535 (beclomethasone dipropionate 100 microg + formoterol 6 microg) pMDI [pressurised Metered Dose Inhaler] via HFA-134a vs. fluticasone 125 microg + salmeterol 25 microg pMDI (Seretide) in the 12-week treatment of adult patients with moderate to severe persistent asthma.

Trial Profile

Double blind, multinational, multicentre, parallel-group design clinical trial of the efficacy and tolerability of CHF 1535 (beclomethasone dipropionate 100 microg + formoterol 6 microg) pMDI [pressurised Metered Dose Inhaler] via HFA-134a vs. fluticasone 125 microg + salmeterol 25 microg pMDI (Seretide) in the 12-week treatment of adult patients with moderate to severe persistent asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Beclometasone/formoterol; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms ICAT-SE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Oct 2007 Study acronym identified
    • 01 Oct 2007 Results have been published, including primary endpoint
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top